{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vismodegib+150+mg", "query": { "intervention": "Vismodegib 150 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vismodegib+150+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-18T22:24:50.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01815840", "title": "A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2013-04-30", "completion_date": "2016-08-31", "has_results": true, "last_update_posted_date": "2017-09-28", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 17, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01815840" }, { "nct_id": "NCT01898598", "title": "A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-01-23", "completion_date": "2016-01-26", "has_results": true, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01898598" }, { "nct_id": "NCT01088815", "title": "Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine, nab-Paclitaxel, GDC-0449", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2010-09-17", "completion_date": "2018-02-17", "has_results": true, "last_update_posted_date": "2019-04-26", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088815" }, { "nct_id": "NCT01201915", "title": "A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 74, "start_date": "2010-10", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-06-24", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01201915" }, { "nct_id": "NCT01880437", "title": "A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes, Myelogenous Leukemia, Acute" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2013-09", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2015-12-15", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 5, "location_summary": "Stanford, California • Ann Arbor, Michigan • Kansas City, Missouri + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01880437" }, { "nct_id": "NCT00959647", "title": "A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Basal Cell Carcinoma", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-09-03", "completion_date": "2014-01-09", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959647" }, { "nct_id": "NCT05538091", "title": "Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "PARP Inhibitor", "Hedgehog Inhibitor" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Buckanovich", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2023-05-15", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538091" }, { "nct_id": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Solid Tumors", "Biliary Cancer", "Salivary Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2014-04-14", "completion_date": "2023-05-24", "has_results": true, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 60, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091141" }, { "nct_id": "NCT05651828", "title": "Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Basal Cell Carcinoma" ], "interventions": [ { "name": "Vismodegib 150 MG Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2023-03-23", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05651828" }, { "nct_id": "NCT01556009", "title": "Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Nevus Syndrome", "Gorlin's Syndrome" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Aminolevulinic acid %20 topical solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCSF Benioff Children's Hospital Oakland", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2012-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2020-11-02", "last_synced_at": "2026-09-18T22:24:50.375Z", "location_count": 3, "location_summary": "Oakland, California • New York, New York", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01556009" } ] }